The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
复制标题
DOI：
10.1002/ajh.23566
复制
发表时间：
2013-12-01
影响因子：
12.8
通讯作者：
Tarella, Corrado
中科院分区：
文献类型：
--
作者：
Rambaldi, Alessandro;Boschini, Cristina;Tarella, Corrado
诊断时外周血淋巴细胞/单核细胞比率(LMR)可作为弥漫性大B细胞淋巴瘤(DLBCL)患者的临床参考指标。我们回顾了从1984年到2012年在四个中心对1057名DLBCL患者的随访结果。通过受试者操作特征(ROC)分析和Harrell‘s C统计量分析LMR作为临床生物标志物。患者的特征是中位年龄61岁，国际预后指数(IPI)评分为>；2的患者占39%，接受利妥昔单抗化疗的患者占66%。LMR被证明对接受以利妥昔单抗为基础的方案治疗的患者的存活率有很强的预测作用，但在那些只接受化疗的患者中则不能。此外，LMR值为
The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of > 2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of